Boehringer Ingelheim
The main objective of this trial is to establish the bioequivalence of the BI 1015550 Formulation C2 (Test, T) and the BI 1015550 Formulation C1 (Reference, R), following a single oral dose administration.
Healthy
BI 1015550 Formulation C2
BI 1015550 Formulation C1 (R) then BI 1015550 Formulation C2 (T)
Phase 1
Study Type : | Interventional |
Estimated Enrollment : | 64 participants |
Masking : | None (Open Label) |
Primary Purpose : | Treatment |
Official Title : | Bioequivalence of the BI 1015550 High Dose Formulation C2 and the BI 1015550 High Dose Formulation C1 (Phase 3 Formulation) Following Oral Administration in Healthy Subjects (an Open-label, Randomised, Single-dose, Two-way Crossover Trial) |
Actual Study Start Date : | May 7, 2024 |
Estimated Primary Completion Date : | August 30, 2024 |
Estimated Study Completion Date : | August 30, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: BI 1015550 Formulation C2 (T) then BI 1015550 Formulation C1 (R) |
Drug: BI 1015550 Formulation C2 Drug: BI 1015550 Formulation C1 (R) then BI 1015550 Formulation C2 (T) |
Experimental: BI 1015550 Formulation C1 (R) then BI 1015550 Formulation C2 (T) |
Drug: BI 1015550 Formulation C2 Drug: BI 1015550 Formulation C1 (R) then BI 1015550 Formulation C2 (T) |
Ages Eligible for Study: | 18 Years to 50 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Accepts Healthy Volunteers |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.